ArticleBMJ (Clinical research ed.)2023
Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study.
Article in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Trial
- Cardiovascular Safety of Hormonal Contraception: Method-Specific Risks and Clinical Implications.Medical sciences (Basel, Switzerland) · 2026Review
- Osteoarthritis and analgesic consumption in haemochromatosis HFE C282Y homozygotes with normal or low iron parameters.Nature communications · 2026Article
- Medical Treatment for Endometriosis: One Size Does Not Fit All.Journal of clinical medicine · 2026Review
- Non-steroidal anti-inflammatory drugs versus acetaminophen and risk of venous thromboembolism: An active comparator new user cohort study.Journal of internal medicine · 2026Article
- Drug-drug interactions between sex hormones and analgesics linked to thromboembolic events: an FDA adverse event reporting system analysis.Frontiers in pharmacology · 2026Article
- Venous thromboembolism and 20-year cancer risk: a Danish population-based cohort study.Research and practice in thrombosis and haemostasis · 2026Article
- Increased risk of thromboembolism in patients with anorexia nervosa: a Danish nationwide registry-based study.BMC medicine · 2025Observational
- Combined Oral Contraceptives and the Risk of Thrombosis.International journal of molecular sciences · 2025Review
- Risk factors for venous thromboembolism after knee arthroscopy: a systematic review and meta-analysis.Thrombosis journal · 2025Review
- Impact of Menstrual Cycle and Oral Contraceptives on Haematological and Inflammatory Biomarkers in Highly Trained Female Athletes.Drug testing and analysis · 2025Article
- Electro-Acupuncture for Diminished Ovarian Reserve: Protocol for a Randomized, Placebo-Controlled Trial.Journal of multidisciplinary healthcare · 2025Article
- Is fluid retention a cardiovascular risk factor?Clinical hemorheology and microcirculation · 2024Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the influence of concomitant use of hormonal contraception and non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of venous thromboembolism.
designNationwide cohort study.
settingDenmark through national registries.
participantsAll 15-49 year old women living in Denmark between 1996 and 2017 with no medical history of any venous or arterial thrombotic event, cancer, thrombophilia, hysterectomy, bilateral oophorectomy, sterilisation, or infertility treatment (n=2 029 065).
main outcome measureA first time discharge diagnosis of lower limb deep venous thrombosis or pulmonary embolism.
resultsAmong 2.0 million women followed for 21.0 million person years, 8710 venous thromboembolic events occurred. Compared with non-use of NSAIDs, use of NSAIDs was associated with an adjusted incidence rate ratio of venous thromboembolism of 7.2 (95% confidence interval 6.0 to 8.5) in women not using hormonal contraception, 11.0 (9.6 to 12.6) in women using high risk hormonal contraception, 7.9 (5.9 to 10.6) in those using medium risk hormonal contraception, and 4.5 (2.6 to 8.1) in users of low/no risk hormonal contraception. The corresponding numbers of extra venous thromboembolic events per 100 000 women over the first week of NSAID treatment compared with non-use of NSAIDs were 4 (3 to 5) in women not using hormonal contraception, 23 (19 to 27) in women using high risk hormonal contraception, 11 (7 to 15) in those using medium risk hormonal contraception, and 3 (0 to 5) in users of low/no risk hormonal contraception.
conclusionsNSAID use was positively associated with the development of venous thromboembolism in women of reproductive age. The number of extra venous thromboembolic events with NSAID use compared with non-use was significantly larger with concomitant use of high/medium risk hormonal contraception compared with concomitant use of low/no risk hormonal contraception. Women needing both hormonal contraception and regular use of NSAIDs should be advised accordingly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.